BGM0504
A Study of BGM0504 Injection in Participants With Obesity or Overweight
BrightGene Bio-Medical Technology Co · Phase 3 · Completed · Enrollment 652
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 5 mg BGM0504 injection | n/r | n/r | n/r | n/r |
| 10 mg BGM0504 injection | n/r | n/r | n/r | n/r |
| 15 mg BGM0504 injection | n/r | n/r | n/r | n/r |
| BGM0504 placebo | n/r | n/r | n/r | n/r |
Not shown
- 5 mg BGM0504 injection: endpoint not reported
- 10 mg BGM0504 injection: endpoint not reported
- 15 mg BGM0504 injection: endpoint not reported
- BGM0504 placebo: endpoint not reported